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Objectives: To explore whether 4-day parenteral p-lactam ther- 
apy is as effective as 7-day therapy for children hospitalized for 
parenteral antimicrobials. 
Methods: A series of patients aged 3 months to 15 years who 
fulfilled strict criteria for bacterial pneumonia, other respiratory 
infections, sepsis-like infections, and other acute infections 
were prospectively randomized to receive parenteral penicillin 
or cefuroxime randomly for 4 or 7 days. Besides blood and 
throat cultures, the etiology was searched by serology for 23 
different agents. 
Results: Of 154 children analyzed, a probable etiology was 
established in 96. Of those, a bacterial infection, with or with- 
out concomitant viral infection, was disclosed in 80% and 94% 
in the 4-day and 7-day treatment groups, respectively; pneu- 
mococcus being the commonest agent. There was one pos- 
sible treatment failure in the 4-day group, but with a 
questionable relation to the short course. Three patients in the 
4-day and two in the 7-day group underwent treatment 
changes, or were rehospitalized within 30 days. All children 
recovered entirely. 
Conclusions: Shortening parenteral p-lactam treatment to 
4 days in infections for which most parenteral antimicrobials are 
instituted, is not only safe, but reduces costs, is ecologically 
sound, and minimizes the risks of nosocomial infections and 
other adverse effects of treatment. 
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Pneumonia, other acute lower respiratory infections, and 
various other bacteremic or nonbacteremic processes are 
the most common indications for hospitalization and 
administering a 7- to IO-day course of parenteral anti- 
microbials. Little is known about whether a treatment 
period of this length is needed. Curiously, even with the 
best laboratory and other facilities, most of these com- 
monly seen patients are discharged without the etiology 
determined, in contrast to those with meningitis or osteo- 
articular or urinary tract infections. However, except for 
the latter infections, those diseases are rare. Among other 
undesirable effects, long treatments increase resistance 
problems; a good example is the reduced susceptibility 
of Streptococcus pneumoniae to penicillin, which is 
increasing at alarming rates in Europe and elsewhere.’ 
In response to the urgent need for new therapeutic 
approaches,z.A the authors established a prospective and 
randomized study focusing on children, who form the 
overwhelming majority of patients for whom parenteral 
antimicrobials are given. A p-lactam antimicrobial, pro- 
caine penicillin (50,000 IU/kg once daily intramuscularly) 
or cefuroxime (100 mg/kg per day in 3 divided doses 
intravenously), was always used,” and the duration of 
medication was randomized to last 4 or 7 days. This 
degree of the treatment shortening was deemed justified 
on the basis of what is known of the short duration of 
treatment proven successful in lower urinary tract infec- 
tions in adults and meningococcal meningitis.j,” 
PATIENTS AND METHODS 
Patients and Inclusion Criteria 
A total of 178 infants and children were enrolled prospec- 
tively from Helsinki University Central Hospital, Hospital 
for Children and Adolescents, and Aurora Hospital, 
Helsinki, Finland. To ensure that all common agents cir- 
culating periodically in the community were included, 
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enrollment took place over two periods, in 1988 to I989 
and 1991 to 1993. The ethical committee approved the 
study protocol, and oral consent was obtained from the 
guardians of each child. 
A patient was included in the study if he or she pre- 
sented with acute clinical signs and symptoms of infec- 
tion, appeared toxic, or was otherwise ill enough to be 
hospitalized for parenteral antimicrobials7” The clinical 
judgment was the most important parameter, but detailed 
instructions were formulated to unify the inclusion cri- 
teria. In doubtful cases, guidance was sought from radio- 
graphic and laboratory investigations, such as serum 
C-reactive protein (CRP).9 If CRP exceeded 80 mg/L, the 
child was enrolled and antimicrobial treatment was insti- 
tuted, whereas with values between 20 mg/L and 79 mg/L 
the child was hospitalized, and CRP was checked within 
8 to 12 hours. If CRP had increased by at least 50%, as it 
characteristically does in invasive bacterial infections, lo 
the child was included, and antimicrobial treatment was 
started. If neither of these criteria was fulfilled, he or she 
was monitored clinically, and therapy began only if the 
condition deteriorated. A steadily unincreased (~20 mg/L) 
CRP was taken as suggestive of viral disease.” 
The exclusion criteria were the following: age less 
than 3 months or more than 15 years, immunocompro- 
mise, meningitis, osteoarticular or urinary tract infections, 
or a condition requiring surgery or intensive care. 
Disease Manifestations and Treatment 
According to the clinical presentation and the radio- 
graphic and laboratory findings, the patients were divided 
into four categories: pneumonia (acute respiratory symp- 
toms and alveolar consolidation in chest radiograph), 
other respiratory infections (as for pneumonia, but with- 
out alveolar consolidation), sepsis-like infections (clini- 
cally ill but no respiratory symptoms, fever at least 385°C 
[101.3”F],and an initial CRP 100 mg/L),s,9 and other likely 
bacterial infections (clinically ill enough to receive anti- 
microbials but no respiratory symptoms, low fever, or 
only marginally increased CRP),’ cellulitis and lym- 
phadenitis were examples in this category.” 
The randomization of medication for 4 days or 7 days 
was done by a computer-generated list kept at the Uni- 
versity Hospital, to assign patients in the four groups. The 
scheduled treatment was marked on the individual charts 
in advance. Patients with potential penicillin allergy were 
scheduled in the cefuroxime group. If parents of children 
in the 7-day treatment group refused to let them stay in 
hospital the whole week, treatment was continued at 
home with large doses of oral penicillin V or cefuroxime 
axetil until the -/-day course was completed. 
Etiology 
The laboratory methods and cutoff values used are 
described in detail elsewhere.‘l In short, blood cultures 
were taken from all patients and, in addition, throat cul- 
tures from those with tonsillitis. In addition, 23 bacter- 
ial, viral, or protozoa1 agents were screened for, using 
paired sera collected on admission and 2 to 3 weeks 
after hospitalization. 
The following bacteria were searched for: S. pneu- 
moniae, Haemophilus influenzae, Staphylococcus 
aureus, Mycoplasma pneumoniae, Moraxella 
catarrhalis, Chlamydia pneumoniae, and Chlamydia 
trachomatis. Special emphasis was given to pneumo- 
coccal serologic testing. Pneumolysin IgG antibodies were 
measured by enzyme immunoassay (EIA) in which a two 
fold or greater increase in titer was taken as diagnos- 
tic.‘2.‘3 For C-polysaccharide and pneumolysin-specific 
immune complexes, a single high optical density (value 
of at least 400 or 550, respectively), was deemed diag- 
nostic.‘*-‘” For other agents, diagnostic tests were per- 
formed as previously described.” 
Viral diagnoses were sought for influenza A and B, 
parainfluenza 1, 2, and 3, adenovirus, respiratory syncy- 
tial (RS) virus, coxsackie virus B5, herpes simplex, human 
herpes virus 6 (HHV 6), rotavirus, cytomegalovirus, 
varicella zoster, mumps, and Epstein-Barr viruses, by sero- 
logy. Influenza A and B, parainfluenza 1,2, and 3, adeno- 
virus, and RS viruses were also looked for by antigen 
detection from nasopharyngeal aspirates. Toxoplasma 
antibodies were also screened for in serum samples.” 
Follow-up 
Each patient had a follow-up form filled out daily through- 
out hospitalization, and various laboratory and radio- 
graphic tests were obtained at predetermined intervals. 
A control visit was scheduled 2 to 3 weeks after hospi- 
tal discharge. Whether the child had spontaneously vis- 
ited a private physician or another hospital within 30 days 
after hospitalization was also determined. 
Statistics 
The primary endpoint for successful treatment was 
uneventful recovery (no change in the scheduled treat- 
ment). Sample size calculations showed that, with two 
treatment groups, a total of 142 patients would be required 
to detect a 20% difference in effectiveness at a level of P 
< 0.05 (two-sided test) with a power of 80%. Student’s 
unpaired two-tailed t-test or analysis of variance (ANOVA) 
was used to test potential differences between the means 
of continuous variables, and &i-squared tests were used 
for testing category variables. The tests were two-sided, 
and the level of significance was set at P < 0.05. 
RESULTS 
In all, 178 patients were enrolled, of whom 24 (13%) 14 
in the 4day and 10 in the 7day group, were excluded for 
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the following reasons: 8 had an underlying disease,” in 
5 cases the scheduled antimicrobial was discontinued 
within 24 hours because the clinician was convinced of 
viral illness; 4 developed otitis and 2 streptococcal ton- 
sillitis (which required prolonged treatment with another 
oral agent); 1 case was considered to be listeriosis, and 
in another case, opening of an intravenous line was not 
successful. Finally, parents withdrew two children from 
the study, and in one case the protocol was not followed 
for unknown reasons. Hence, 154 patients were analyzed; 
73 (47%) were in the 4day and 81 (53%) in the 7-day 
treatment groups. There were 86 males and 68 females. 
Initial Characteristics 
At presentation, the groups were comparable (Table 1). 
Slightly more irritable (33% vs 17%; P = 0.03) patients 
were randomized to the 4-day group. 
The laboratory and radiographic indices used did not 
differentiate the groups. C-reactive protein levels 
exceeded 80 mg/L in 82% of children in the 4day and in 
78% of -/-day group. This strongly suggests that the major- 
ity of children had an invasive bacterial infectionYJ” A 
50% increase within 8 to 12 hours was found in an addi- 
tional 8% in the short- and 10% in the long-treatment 
group. The mean CRP values were 131 mg/L and 
132 mg/L, and erythrocyte sedimentation rates 59 mm/h 
and 50 mm/h, respectively Pneumonia was found in 48%, 
and 49% respectively. Pretreatment antimicrobials had 
been given in eight and seven cases, respectively. 
Disease Manifestation and Microbiologic Etiology 
Pneumonia (46%), other respiratory infections (15%) sep- 
sis-like infections (25%) and other acute infections (14%) 
were diagnosed in the 4-day treatment group; in the 7day 
group, the corresponding figures were 47%, 17%, 21%, 
and 15%. Overall, a probable etiology was established in 
62% (45/73) of cases in the short- and 63% (51/81) in 
the long-treatment groups (Table 2). 
Serologic findings established most etiologic diag- 
noses, since bacteriologic confirmation was achieved in 
only 10 cases, as is typical in the industrialized 
world. 17,‘* In eight cases, blood culture proved positive 
(6 yielded S. pneumoniae, 2 H. injluenzae type b), 
whereas the throat culture identified two cases of 
group A streptococcal tonsillitis. Overall, evidence for 
bacterial infection, alone or with viruses, was obtained 
in 80% (36/45) and 94% (48/51) of the cases with the 
probable etiology disclosed in the short- and the long- 
treatment group, respectively. There were more mixed 
bacterial-viral infections in the 4-day group (22% vs. 4%; 
P = 0.02). 
Streptococcuspneumoniae was overwhelmingly the 
most common agent found, being identified in 25 and 
34 cases in the 4-day and 7-day treatment groups, respec- 
tively. Adenoviruses were detected in six cases in which 
concomitant bacterial infections were unlikely. The dis- 
tribution of the etiologic agents identified is summarized 
in Table 2. 
Table 1. Pretreatment Characteristics 
Treatment Group 
4-Day (n = 73) 
Percentage 
Characteristic Number (Standard Error of Mean) 
Demographics 
60~s (n) 37 51 
Girls (n) 36 49 
Mean (y) age 3.8 - 
Previous antimicrobials (n) 8 11 
Clinical features 
Severely il l (n) 23 32 
Impaired consciousness (n) 6 8 
Irritability (n) 24* 33 
Temperature (mean) 39.1 “C, 102.4”F 
Cough (n) 37 51 
Respiratory symptoms (n) 25 34 
Diarrhea (n) 5 7 
Vomiting (n) 18 25 
Laboratory studies 
C-reactive protein (mg/L) 131 (7.97) 
Erythrocyte sedimentation rate (mm/h) 59 (5.20) 
White blood cell count (x 1 Og/L) 21.6 (1 .lO) 
Thrombocytes (X 1 O12/L) 324 (12.04) 
Pneumonia on chest x-ray (n) 34 48+ 
*P < 0.05; + Chest radiograph obtained in 71 and 78 cases, respectively. 
7-Day (n = 81) 
Percentage 
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Table 2. Microbial Etiology and Clinical Outcome of Patients 
Treatment Group 
4-Day (n = 73) 7-Day (n = 81) 
Number Percentage Number Percentage 
Probable microbial etiology 
S. pneumoniae alone 15 33* 24 47 
S. pneumoniae with other agent any 10 22 10 20 
Other bacteria, alone or in combinations 8 18 14 27 
Mixed bacterial-viral infections lo+ 22 2+ 4 
Etiology disclosed in all 45 62 51 63f 
Clinical outcome 
Medication completed as planned 71 971 50 62* 
Possible treatment failure 15 0 
Treatment changed or prolonged 2 1 
Rehospitalization within 1 mo 1 1 
Visit to outpatient department/private physician’s office within 1 mo 4/2 6/2 
Fever without localizing signs1 2 3 
Gastroenteritisc 1 0 
Acute otitis median 3 1 
Obstructive bronchitisc 0 1 
Tonsillitis! 0 1 
Pharyngitisn 0 1 
Nasophat-yngitisn 0 1 
*Percent of those with probable etiology disclosed by culture or serology; +P < 0.05; iof the whole series; %he case probably unrelated to short-course treatment (see 
text); “diagnoses of the outpatient department and private physician combined. 
Clinical Outcome 
There was no difference in clinical outcome between the 
treatment groups (see Table 2). The course was com- 
pleted parenterally as scheduled in 97% (71/73) of the 
4-day and 62% (50/81) of the 7-day group; 38% of children 
in the latter group completed their medication orally 
because of the refusal of parents to have their children 
stay longer in hospital. 
One potential treatment failure was found in the 
4day group (see Table 2) but was probably not in rela- 
tion to the short treatment. A girl at the age of 4 years 
with bilateral pneumonia responded well to cefuroxime, 
but new respiratory symptoms and signs developed 
2 days after discontinuation of medication. Procaine peni- 
cillin led to an uneventful recovery. Cultures proved 
negative on both occasions, but serology suggested a 
combined pneumococcal and HHV 6 infection. Con- 
comitant viral infection makes it difficult to interpret 
whether the case was a true failure. 
Three additional patients, two in the 4-day group and 
one in the 7-day group, underwent a change in treatment. 
A 2-year-old girl presented with periorbital cellulitis. A 
suboptimal initial response to penicillin prompted a 
change to cefuroxime, and her signs and symptoms sub- 
sided gradually. Blood cultures remained negative, but 
since agents beyond the easy reach of penicillin often 
cause cellulitis,‘” this case was more likely a failure of 
penicillin than of the short-term treatment. The second 
case was a 5-year-old girl with C. trachomatis pneumo- 
nia, an infection outside the spectrum of any p-lactam. 
The third case was a 2-year-old boy with pneumonia. 
Sensitive S. pneumoniue (minimal inhibitory concentra- 
tion [MIC] = 0.1 pg/mL) grew from the blood culture, and 
the patient responded well to a ‘-/-day course of procaine 
penicillin. However, a new respiratory infection devel- 
oped after cessation of treatment. Further blood cultures 
remained negative. Uneventful recovery followed treat- 
ment with cefuroxime. It is unlikely that pneumococcal 
pneumonia would not have been cured by a week-long 
treatment, such a case has probably never been docu- 
mented.*O The authors deemed the relapse to be attrib- 
utable to an unidentified secondary infection. 
Follow-up 
Two other children were readmitted within 1 month of 
discharge: an l&month-old boy in the 4-day group devel- 
oped diarrhea and was rehospitalized for rehydration, 
and a 6-year-old boy in the 7day group developed pneu- 
monia 4 weeks after discharge. In both instances, a causal 
relation to the primary infection was unlikely. 
In all, 133 children (86%) attended the control visit 
2 to 3 weeks following hospital discharge. In the major- 
ity, all symptoms and signs had subsided. Ten children, 
four in the short- and six in the long-treatment group, 
revisited the outpatient department spontaneously within 
1 month after hospitalization. There was not any reason 
to suspect failure of earlier treatment. All patients 
returned home. The diagnoses were fever without focal 
signs (n = 5) acute otitis media (n = 2) nasopharyngitis 
(n = l), obstructive bronchitis (n = l), and gastroenteri- 
tis (n = 1). Another four children consulted a private 
physician within 30 days, two for acute otitis media, one 
Shortening of Antimicrobial Therapy / Peltola et al 7 
for streptococcal tonsillitis, and one for pharyngitis; oti- 
tis and tonsillitis were treated with antimicrobials. Dis- 
tribution of all these 14 children is summarized in Table 
2. 
DISCUSSION 
Many bacterial infections are treated for unnecessarily 
long periods,’ solely based on criteria that are more sub- 
jective than objective. *’ Sometimes shorter courses have 
become well established. Medication for staphylococcal 
osteomyelitis has been reduced to 3 weeksz2; a 3-day 
course of cotrimoxazole or a 5day course of a p-lactam 
is as efficacious as any treatment for acute cystitis in 
women5; and a perforated appendix may be treated any- 
where from 1 to 10 days.2” Another example is non- 
neonatal bacterial meningitis (in an immunocompetent 
host): no benefit is achieved with more than 7 days of 
ampicillin or third generation cephalosporins in H. 
influenzae and pneumococcal meningitis,2”,‘5 whereas 
in meningococcal meningitis, a single intramuscular 
injection of long-acting penicillin or chloramphenicol 
suffces.z”,2- 
eluded that prolonging p-lactam treatment for longer than 
4 days provides no added benefits. Instead, short-term 
antimicrobial treatment decreases the general costs of 
treatment and the risks of nosocomial infection, allergy, 
and other adverse outcomes, and is ecologically sound. 
Although penicillin-resistant pneumococci were not 
encountered in this study, 1,31 they should not be a prob- 
lem for short-term treatment of nonmeningeal diseases, 
because these strains still respond well to penicillin, at 
least if used in high doses. 20.j2 Beta-lactamase-positive 
strains restrict the use of penicillin in several countries, 
but in Finland, and in many other countries as well, iso- 
lation of those from invasive infections is rare. Curiously 
enough, even the P-lactamase-positive strains have not 
been shown to be unresponsive to ampicillin or amoxi- 
cillin treatment in immunocompetent patients.“2,“3 
The authors’ conclusions might be challenged 
because the etiology remained sometimes unproven, 
despite intense search for microbiologic causes (23 bac- 
terial, viral, or protozoa1 agents). However, in 62% of cases 
the probable etiology was disclosed, and this result com- 
pares favorably with virtually all earlier series.28-3” Fur- 
thermore, all children were considered ill enough to 
require costly hospitalization and parenteral antimicro- 
bials, and the laboratory parameters performed (see Table 
1) strongly favored this decision.T,8 An invasive bacterial 
infection was most likely in almost all children ~recruited 
in this particular study. 
The results also highlight the difficulties in the micro- 
biologic diagnosis of infections for which most anti- 
microbials in hospital are ordered. Even in the best 
centers the majority of these patients remain without set- 
tled etiology. Series on pneumonia and bacteremia have 
been published,28-“” but this study is the first that com- 
pared alternative duration of treatment in children with 
a wide disease spectrum. The variability of patients 
reflects the existing realities in the on-call circumstances 
throughout the world. 
Uneventful recovery was the primary endpoint for 
successful treatment. Duration of fever alone was not 
used as an outcome measure because antipyretics are 
given frequently to pediatric patients, and the same agents 
also are used as analgesics. Although not all patients had 
a follow-up visit after discharge, the results were valid 
because had any relapse occurred, it would have been 
treated in the participating centers. 
Since children in the 4-day group were no less ill 
than those in the -i-day group (see Table l), it is con- 
The data might be relevant for the treatment of chil- 
dren throughout the world, although more studies along 
these lines are warranted, and these results might not be 
directly applicable to other settings. Nevertheless, short- 
duration treatments have been found effective in pediatric 
urinary tract infections.34 The present results should also 
raise questions about traditional treatment policies in 
other common infections.7,‘5 Long courses promote 
antimicrobial resistance,‘” and in the developing world, 
many patients are left without adequate treatment 
because costly antimicrobials are reserved for families 
affluent enough to afford the costs.j’,38 inexpensive drugs 
and treatments are a necessity.j” Shortening of treatment 
from 7 to 4 days in children hospitalized for parenteral 
antimicrobials seems often justified. 
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